Those with decreased ACE2 levels are also those who have been seen to have more severe COVID-19 cases—this includes people with chronic diseases, elderly, and males. It's been hypothesized that since ACE inhibitors and ARBs (angiotensin II receptor blockers) increase ACE2, they may reduce the risk of severe disease in these populations that are at risk.